The Munich-based WILEX AG announced on August 24th that thecombined capital increase against cash and in kind contributions was successfully completed with a total of 23.9 million euros. The main part of the new shares goes to the shareholder dievini Hopp BioTech, who converted an existing loan and additionally invested. Thus, the loan will redeemed, without burdening the liquidity of the company.
The company will receive gross proceeds of about 16.1 million euros from the cash portion of the transaction. The oncology specialist WILEX plans to invest the proceeds in further growth and to finance ongoing and further planned clinical trials.
In the fourth quarter of this year, the results of the phase III study of therapeutic antibody RENCAREX in the indication renal cancer are expected. Among the more advanced candidates, is also the small molecule Mesupron against the indication of pancreatic cancer and breast cancer.
To the press release from WILEX AG